XBiotech announced today that Dr. Alice Gottlieb, M.D., Ph.D., will be giving the presentation “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the afternoon session on March 2nd, 2019 at the American Aacademy of Dermatology annual meeting being held at the Walter E. Washington Convention Center in Washington, D.C. The presentation, which was accepted as “late-breaking research: clinical trials,” will provide details of the Company’s recent Phase II clinical trial results in 42 HS patients that received 400mg subcutaneous weekly doses of bermekimab in a 12-week treatment regimen.
The study involved two treatment groups of subjects: those who had failed prior anti-TNF therapy (n=24); and those with no prior anti-TNF treatment history (n=18).
The study’s Chair, Dr. Alice Gottlieb, M.D., Ph.D., Clinical Professor of Dermatology, Department of Dermatology, Icahn School of Medicine at Mount Sinai, NY, NY, commented, “I am looking forward to presenting these very exciting results for a new drug that can help address a significant unmet need for patients suffering from hidradenitis suppurativa.”
A major finding in the study was a significant treatment-related reduction of pain in the HS patients. Pain is widely recognized among experts as a key objective for HS treatment, but this symptom has been largely unaddressed by available approved therapies. No approved monotherapy for HS has shown a significant effect on pain1.
Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin disorder affecting areas rich in apocrine glands. Nodules appear in the affected areas and progressively become swollen with spontaneous rupture and release of pus. This process occurs repeatedly leading to formation of deep sinus tracts and painful dermal abscesses. Pain is a paramount condition in patients suffering from HS, as this chronic inflammation and accompanying pain account for the fact that HS is ranked first among skin disorders in terms of adversely affecting quality of life. The global prevalence for HS is estimated at up to 4% of the population.
Header Photo Credit: Dermatology World